Sarcoma Diagnosis and TreatmentEpigenetics and DNA MethylationCancer Genomics and DiagnosticsHistone Deacetylase Inhibitors ResearchPARP inhibition in cancer therapy
Publications
112
Citations
1,337
Est. group size
—
Recurring co-author estimate
Active years
51
Publishing since 1976
Publication cadence
Publications per year over the last 10 years — averaging 15.2/year recently
Recent publications
- FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Cancer Research · 2026
- Supplemental Note 1 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Table 1 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Note 3 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Figure 7 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Note 2 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Figure 5 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Figure 1 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Table 2 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Figure 4 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Figure 3 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Figure 6 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Data from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Note 4 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
- Supplemental Figure 2 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
2026
Publishes in
- Cancer Research×20
- Clinical Cancer Research×3
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Cancer Discovery×2
- Tumor Biology×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile